A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Over the past few years, a number of studies have suggested that the treatment of major depressive disorder (MDD) with anti-depressants enhancing both noradrenergic as well as serotonergic neurotransmission may result in higher response or remission rates than treatment with anti-depressants selectively enhancing serotonergic neurotransmission. The objective of this paper was to compare response rates among patients with MDD treated with either mirtazapine, an anti-depressant thought to simultaneously enhance both noradrenergic and serotonergic neurotransmission, or selective serotonin reuptake inhibitors (SSRIs). Medline/Pubmed were searched. No year of publication limits were used. Double-blind, randomized clinical trials comparing mirtazapine with an SSRI for the treatment of MDD. Data were extracted with the use of a pre-coded form. Analyses were performed comparing response rates between the two anti—depressant agents. Data from 10 reports involving a total of 1904 outpatients with MDD were identified and combined using a random-effects model. Patients randomized to treatment with mirtazapine were as likely to experience clinical response as patients randomized to treatment with an SSRI (RR = 1.07; 95% CI: 0.96—1.2, P = 0.181). Simply pooling response rates between the two agents revealed a 67.1% response rate for mirtazapine and a 62.1% response rate for the SSRIs. There was no difference in overall discontinuation rates (RR = 1.1; 95% CI: 0.7—1.5; P = 0.550), discontinuation rates due to adverse events (RR = 0.9; 95% CI: 0.6—1.2; P = 0.497), or discontinuation rates due to lack of efficacy (RR = 0.9; 95% CI: 0.4—2.0; P = 0.871) between the two groups. Fewer mirtazapine-treated patients complained of insomnia (RR = 0.5; 95% CI: 0.3—0.9; P = 0.017), nausea (RR = 0.3; 95% CI: 0.3—0.5; P < 0.0001), whereas fewer SSRI-treated patients complained of fatigue (RR = 1.5; 95% CI: 1.1—2.4; P = 0.028), excessive sleepiness (RR = 1.3; 95% CI: 1.1—1.7; P = 0.020), weight-gain (RR = 3.8; 95% CI: 2.3—6.4; P < 0.0001) or dry mouth (RR = 1.8; 95% CI: 1.3—2.4; P < 0.0001) during the course of treatment. These results suggest that mirtazapine and the SSRIs differ with respect to their side-effect profile but not their overall efficacy in the treatment of MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Self-citationGoldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Is there a delay in the antidepressant effect? A meta-analysis
Posternak, M. A., & Zimmerman, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0201 · Cited by 250
Understanding research synthesis (meta-analysis).
Mosteller, F., & Colditz, G. A. (1996) · Annual Review of Public Health · doi:10.1146/annurev.pu.17.050196.000245 · Cited by 228
Winokur, A., DeMartinis, N. A., McNally, D. P., Gary, E. M., Cormier, J. L., & Gary, K. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1013 · Cited by 165 · cited 2×
“…involved a total of 1904 MDD outpatients randomized to treatment with mirtazapine and either fluoxetine (Wheatley et al., 1998; Hong et al., 2003; Winokur et al., 2003; Amini et al., 2005; Versiani et al., 2005), sertraline (Behnke et al., 2003), paroxetine (Benkert et al., 2000; Schatzberg et…”
BackgroundMethodLeinonen, E., Skarstein, J., Behnke, K., ??gren, H., & Th Helsdingen, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199911000-00002 · Cited by 146
Haddjeri, N., Blier, P., & de Montigny, C. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199512004-00003 · Cited by 137 · cited 2×
“For this reason, it is thought that the acute administration of mirtazapine produces a rapid increase in both noradrenergic and serotonergic neurotransmission, resulting in an enhanced tonic activation of postsynaptic serotonergic receptors (Haddjeri et al., 1995; for review see Blier, 2001a, b; Blier, 2003).”
Background
Cited by
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Self-citationLekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Insomnia and depression: a multifaceted interplay
Manber, R., & Chambers, A. S. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0066-1 · Cited by 134
“Mirtazapine, trazodone, and nefazodone result in nearly half the rate of disturbed sleep compared with SSRIs [ 45 ,46], whereas those taking reboxetine report twice the rate of sleep disturbance [47].”
BackgroundResultNegr1 controls adult hippocampal neurogenesis and affective behaviors
Noh, K., Lee, H., Choi, T.-Y., Joo, Y., Kim, S.-J., Kim, H., Kim, J. Y., Jahng, J. W., Lee, S., Choi, S.-Y., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0347-3 · Cited by 86
Papakostas, G. I., Nelson, J. C., Kasper, S., & Möller, H.-J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.07.005 · Cited by 73
Self-citation
Metadata
- Authors
- Papakostas, G., Homberger, C., & Fava, M.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-02-28
- Volume
- 22
- Issue
- 8
- Pages
- 843-848
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1976275668
- Cited by
- 109
- References
- 9
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. https://app.cochat.ai/papers/10.1177/0269881107083808
- The paper
- Papakostas, G., Homberger, C., & Fava, M. (2008). A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Journal of Psychopharmacology. https://doi.org/10.1177/0269881107083808
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.